SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

13 Feb 2024 Evaluate
The sales for the December 2023 quarter moved down to Rs. 266.60 millions as compared to Rs. 317.05 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -14.58 millions as compared to Net Loss of Rs. -49.18 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 improved to 10.57% as compared to -16.04% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 266.60 317.05 -15.91 815.19 942.45 -13.50 1295.68 1371.27 -5.51
Other Income 0.04 8.60 -99.53 0.92 8.73 -89.46 18.05 2.75 556.36
PBIDT 10.57 -16.04 -165.90 62.38 -100.59 -162.01 -47.89 162.72 -129.43
Interest 4.41 4.29 2.80 13.72 12.78 7.36 41.61 0.40 10302.50
PBDT 6.16 -20.33 -130.30 48.66 -138.05 -135.25 -288.47 83.72 -444.57
Depreciation 26.80 30.88 -13.21 80.12 92.49 -13.37 134.19 145.11 -7.53
PBT -20.64 -51.21 -59.70 -31.46 -230.54 -86.35 -422.66 -61.39 588.48
TAX -6.06 -2.03 198.52 32.85 5.54 492.96 -36.45 -8.07 351.67
Deferred Tax -6.06 -2.03 198.52 32.85 5.11 542.86 -36.88 -14.55 153.47
PAT -14.58 -49.18 -70.35 -64.31 -236.08 -72.76 -386.21 -53.32 624.32
Equity 501.01 406.73 23.18 501.01 406.73 23.18 501.01 406.73 23.18
PBIDTM(%) 3.96 -5.06 -178.37 7.65 -10.67 -171.70 -3.70 11.87 -131.15

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×